Director dealings: Avon Technolgies' Rich Cashin sells shares

Monday’s market has seen swings in various stocks based on news and other factors. Today, stocks like Tesla (TSLA) and Philip Morris (PM) are rallying, while stocks like Edgewise Therapeutics (EWTX) are falling. Below are highlights of some of the biggest stock movers, from mega-caps to small caps.

Mega-Cap Movers

(Market Cap $200 billion USD or higher)

• Micron Tech (MU) +1.71%
• Philip Morris Intl (PM) +1.94%
• Tesla Motors (TSLA) +1.46%

Large-Cap Stock Movers

(Market Cap $10-$200 billion USD)

• dMY Technology Group III (IONQ) +9.26%
• New Providence Acquisition Corp N (ASTS) +7.38%
• Vector Acquisition (RKLB) +7.18%
• Kratos Defense & (KTOS) +6.99%
• Iris Energy (IREN) +6.21%
• Joby Aviation (JOBY) +6.08%
• Coherent (COHR) +5.76%
• Yandex (NBIS) +4.86%
• Coeur dAlene Mines Corp (CDE); New Gold shareholders to vote on $20 bln Coeur Mining acquisition +3.32%
• Astera Labs (ALAB) +5.23%

Mid-Cap Stock Movers

(Market Cap $2-$10 billion USD)

• DPCM Capital (QBTS); D-Wave to showcase quantum computing applications at CES 2026 +14.95%
• Hut 8 Mining PK (HUT) +14.22%
• CF Acquisition Corp VI (RUMBW) +14.08%
• Applied Opt (AAOI) +14.05%
• Unifirst Corp (UNF) +13.99%
• Cytokinetics (CYTK) +12.07%
• Rigetti Computing Inc (RGTI) +10.19%
• Quantum Computing OTC (QUBT) +10.79%
• Clearwater Analytics Holdings (CWAN) +8.22%
• Edgewise Therapeutics (EWTX) -11.29%

Small-Cap Stock Movers

(Market Cap $300 million - $2 billion USD)

• Mudrick Capital A (HYMC); Hycroft reports record silver grades in Nevada mine expansion +45.92%
• Tessera Tech (ADEA); Adeia raises 2025 revenue guidance after Disney deal +28.31%
• Osprey Technology Acquisition (BKSY); Jefferies initiates coverage on BlackSky Technology stock with Buy rating +16.78%
• IONX (IONX) +17.44%
• Unusual Machines (UMAC) +18.69%
• United States Antimony Corp (UAMY) +14.94%
• TimefireVR (RCAT) +14.04%
• Armada Acquisition I (RZLV) +16.47%
• PharmAthene Inc (ALT) +8.72%
• DMARKET ADR (HEPS) -21.28%

For real-time, market-moving news, join Investing Pro.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Investing.com -- Altimmune Inc (NASDAQ:ALT) stock plunged 22.8% Friday after the company released 48-week data from its Phase 2b trial of pemvidutide for metabolic dysfunction-associated steatohepatitis (MASH).

The biopharmaceutical company reported that pemvidutide, its glucagon/GLP-1 dual receptor agonist, achieved statistically significant improvements in non-invasive markers of fibrosis compared to placebo. The 1.8 mg dose showed continued weight loss from the 24-week to 48-week timepoint without plateauing, with patients achieving 7.5% weight loss versus 0.2% for placebo.

Despite these positive results, investors appeared disappointed with the data, sending shares sharply lower. The trial showed that patients receiving pemvidutide 1.2 mg and 1.8 mg doses achieved mean reductions in Enhanced Liver Fibrosis (ELF) scores of -0.49 and -0.58 respectively, compared to +0.16 in placebo-treated patients.

The company also reported reductions in Liver Stiffness Measurement (LSM), with the 1.2 mg and 1.8 mg doses achieving mean reductions of -3.04 and -3.67 kPa respectively, versus -0.12 kPa in the placebo group.

Altimmune emphasized the drug’s favorable tolerability profile, with adverse events leading to treatment discontinuation occurring in 0% and 1.2% of patients treated with pemvidutide 1.2 mg and 1.8 mg respectively, compared to 3.5% of participants on placebo.

The company plans to advance pemvidutide to a Phase 3 trial in 2026 following a productive End-of-Phase 2 meeting with the FDA, which resulted in alignment on parameters for a registrational trial in MASH patients with moderate to advanced liver fibrosis.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Friday’s market has seen swings in various stocks based on news and other factors. Today, stocks like Oracle (ORCL) and Micron Tech (MU) are rallying, while others are experiencing declines. Below are highlights of some of the biggest stock movers, from mega-caps to small caps.

Mega-Cap Movers ($200B+ Market Cap)

• Micron Tech (MU) +5.6%
• Oracle Corp (ORCL) +6.12%
• Adv Micro Device ( +4.64%
• Lam Research Corp (LRCX) +3.54%
• Nvidia Corp (NVDA) +2.48%
• Applovin (APP) +1.68%
• Palantir Technologies Inc (PLTR) +2.75%
• Caterpillar (CAT) +2.01%
• Avago Technologies (AVGO) +2.12%
• Applied Matls Inc (AMAT) +1.81%

Large-Cap Stock Movers ($10B-$200B Market Cap)

• CoreWeave (CRWV); CoreWeave joins DOE’s Genesis Mission to advance AI in scientific research +17.06%
• Bloom Energy Corp (BE) +11.27%
• Yandex (NBIS) +10.59%
• Vector Acquisition (RKLB) +10.0%
• Carnival Corp-Exch (CCL); Carnival Corp achieves record profits, reinstates dividend +8.95%
• Bitmine Immersion Tech (BMNR) +7.63%
• Lumentum Holdings Inc (LITE) +5.17%
• SanDisk Corp-Exch (SNDK) +6.45%
• Xpeng Inc (XPEV) +6.7%
• Nike (NKE) -8.7%

Mid-Cap Stock Movers ($2B-$10B Market Cap)

• Amicus Therapeutics (FOLD) +30.44%
• BioMarin Pharmaceuticals (BMRN); BioMarin to acquire Amicus Therapeutics for $4.8 billion +19.92%
• Fly Leasing Ltd (FLY); Firefly Aerospace stock initiated at Sector Weight by KeyBanc +12.21%
• Applied Blockchain (APLD) +9.54%
• Hut 8 Mining PK (HUT) +9.6%
• Navan Inc (NAVN) +7.77%
• Grupo Simec BATS (SIM) -9.49%
• Kb Home (KBH); KB Home beats expectations, but shares fall 6% on weak outlook amid housing market challenges -7.59%
• Fs Development Corp (IRON) -12.87%
• Lamb Weston Holdings Inc (LW); Lamb Weston shares tumble 12% despite beating Q2 earnings, revenue estimates -22.54%

Small-Cap Stock Movers ($300M-$2B Market Cap)

• Inflection Point Acquisition (LUNR); Intuitive Machines stock initiated with Overweight rating at KeyBanc +28.85%
• NovaBay Pharmaceuticals Inc (NBY) +28.81%
• Evommune (EVMN) +14.99%
• WhiteFiber (WYFI); WhiteFiber secures $865 million data center deal with Nscale Global +10.59%
• ETHU (ETHU) +12.96%
• FuelCell Energy (FCEL) -10.79%
• Aimei Health Tech (AFJK) -9.53%
• BMNU (BMNU) -0.68%
• Galectin Therapeutics Inc. (GALT); FDA provides feedback on Galectin’s belapectin development program -31.47%
• PharmAthene Inc (ALT) -21.68%

For real-time, market-moving news, join Investing Pro.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.